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Summary 
 
Steroids in the brain arise both from local synthesis and from peripheral sources, and have a 
variety of effects on neuronal function. However, there is little direct chemical evidence for 
the range of steroids present in brain or of the pathways for their synthesis and inactivation. 
This information is a prerequisite for understanding the regulation and function of brain 
steroids. Following extraction from adult male rat brain, we have fractionated free steroids 
and their sulphate esters then converted them to heptafluorobutyrate or methyloxime-
trimethylsilyl ether derivatives for unequivocal identification and assay by gas 
chromatography analysis and selected ion monitoring mass spectrometry. In the free steroid 
fraction, corticosterone, 3α,5α-tetrahydrodeoxycorticosterone, testosterone and 
dehydroepiandrosterone were found in the absence of detectable precursors usually found in 
endocrine glands, indicating peripheral sources and/or alternative synthetic pathways in brain. 
Conversely, the potent neuroactive steroid 3α,5α-tetrahydroprogesterone (allopregnanolone) 
was found in the presence of its precursors pregnenolone, progesterone and 5α-
dihydroprogesterone. Further, the presence of 3β-, 11β-, 17α- and 20α-hydroxylated  
metabolites of 3α,5α-tetrahydroprogesterone implicated possible inactivation pathways for 
this steroid. The 20α-reduced metabolites could also be found for pregnenolone, progesterone 
and 5α-dihydroprogesterone, introducing a possible regulatory diversion from the production 
of 3α,5α-tetrahydroprogesterone. In the steroid sulphate fraction, dehydroepiandrostrone 
sulphate was identified but not pregnenolone sulphate. Although pharmacologically active, 
identification of the latter appears to be an earlier methodological artefact and the compound 
is thus of doubtful physiological significance in the adult brain. Our results provide a basis for 
elucidating the origins and regulation of brain steroids. 
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Introduction 
 
Steroid hormones have long been known to enter the mammalian nervous system to influence 
its development and function. More recently, some steroids have also been shown to be 
present in brain tissue independently of peripheral sources (1-3) the so-called neurosteroids 
(4). In support of this concept, mRNA and protein have been detected in rodent brain for the 
steroidogenic cholesterol P450 side chain cleavage (P450scc or CYP11A1) enzyme and for 
certain other steroid metabolising enzymes (see 5, 6 and Discussion). However, there is a 
paucity of information on the actual steroid content of mammalian nervous tissue. Such 
information is essential for a proper understanding of the regulation and function of steroids in 
the brain. 
 
The first compounds to be defined as neurosteroids were pregnenolone and 
dehydroepiandrosterone (DHEA), which had been detected in adult male rat brain as both the 
free steroids and their 3β-sulphate esters (1, 2). Both the free and sulphated forms of these 
steroids persisted at normal or only slightly reduced concentrations following adrenalectomy 
and gonadectomy, suggesting synthesis within the brain. Comparable evidence has since been 
provided for progesterone and its reduced metabolites 5α-dihydroprogesterone and 3α,5α-
tetrahydroprogesterone (allopregnanolone), although there appears to be more of a 
contribution from the gonads in the female rat (3, 7). Other steroids measured in adult 
mammalian brain include estradiol and testosterone (8, 9), aldosterone, corticosterone and 
3α,5α-tetrahydrodeoxycorticosterone (10-12). In the male rat brain, testosterone, 
corticosterone, aldosterone and 3α,5α-tetrahydrodeoxycorticosterone appear to arise from 
endocrine sources (1, 11, 12).  
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Steroids in the brain are of profound physiological significance. There are well-established 
sites of action for estradiol, testosterone, progesterone, corticosterone and aldosterone through 
transcription factors in the mammalian brain (13, 14). More rapid, non-genomic effects of 
steroids, include those of the 3α,5α-reduced metabolites of progesterone and 
deoxycorticosterone, which are well known to modulate synaptic and extrasynaptic inhibition 
by acting at nanomolar concentrations as enhancers of γ-aminobutyric acid (GABA) at 
GABAA receptors (15, 16). By contrast and at lower (micromolar) potencies, pregnenolone 
sulphate and DHEA sulphate negatively modulate GABAA receptor function and 
pregnenolone sulphate also appears to enhance excitatory glutamate actions at the N-methyl-
D-aspartate receptor. Other rapid and relatively low potency effects of brain steroids on 
neuronal membrane receptors include negative modulation by progesterone of the nicotinic 
acetylcholine receptor (17) and the strychnine-sensitive glycine receptor, positive modulation 
of σ-receptors by DHEA and DHEA sulphate and of voltage-gated K+- and Ca2+-channels by 
pregnenolone sulphate (18, 19). Moreover, there is increasing evidence for interactions 
between transcription factor mediated and non-genomic actions of steroids on the brain (see 
19-23). 
 
Despite the long-standing interest in steroid effects on the mammalian brain, there has to our 
knowledge been no detailed profiling of the steroid metabolites present in this tissue. This 
information could provide a foundation for identifying not only the origins of neuroactive 
steroids but also pathways for their inactivation in the brain. To a large extent, the lack of this 
information reflects technical difficulties. Concentrations of the above steroids have mostly 
been measured in brain tissue by immunoassay, which is generally accepted as the most 
sensitive method for the estimation of these compounds. However, problems with cross-
reactivity of antibodies, especially at the low concentrations of steroid present and with 
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interference from the lipidic, cholesterol-rich tissue matrix, mean that brain extracts require 
fractionation by solvent partitioning and/or liquid chromatography before any confidence can 
be placed on the steroid measurements (24, 25). In some cases, further evidence of brain 
steroid identity has been obtained by gas capillary chromatography-mass spectrometry (GC-
MS). With this technique, as for immunoassay, the steroids in brain extracts require 
fractionation before analysis and in addition need to be stabilised by derivatisation before 
injection onto the GC. However, GC-MS has the advantage that steroid derivatives can 
chemically be identified, both by their retention time on the chromatograph and also by their 
ion fragments in the mass spectrometer. Thus, pregnenolone, DHEA, testosterone, 
progesterone, 5α-dihydroprogesterone and 3α,5α- and 3β,5α-tetrahydroprogesterone have all 
been characterised in rat brain extracts by the appearance of at least two and sometimes more, 
diagnostic ions at the appropriate retention time on GC-MS (7, 8, 26-30). The sulphate esters 
of pregnenolone and DHEA were also identified by GC-MS as their corresponding free 
steroids following solvolysis of brain extracts (1, 2, 26). 
 
Whether estimating brain steroids by immunoassay or by GC-MS, the above studies have 
each only focused on a few compounds at a time and revealed several discrepancies. 
Moreover, studies of steroidogenic enzyme expression suggest that further neuroactive 
metabolites could be produced in rat brain and/or enter from peripheral sources (see 
Discussion). In order to provide a framework in which the physiological actions of 
neurosteroids can be understood, and to facilitate further investigations on the regulation of 
steroid metabolism in the brain and the ways in which these pathways might interact with 
peripheral sources of steroid, we now report a detailed analysis of steroids in adult male rat 
brain, using GC-MS and applying the identification criteria of retention time and diagnostic 
ion ratios at a high level of stringency. The steroids to be screened were chosen from products 
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of enzymes known to be expressed in mammalian central nervous system and peripheral 
endocrine sources. 
  
Materials and Methods 
Chemicals 
Reference steroids were obtained from Sigma-Aldrich, Dorset, UK or Steraloids, Inc., 
Newport, USA. 3H-Progesterone (5106.0 GBq/mmol) was from PerkinElmer LAS Ltd., 
Buckinghamshire, UK  All chemicals were analytical grade from VWR International, 
Leicestershire, UK or Sigma-Aldrich, unless stated otherwise and the solvents re-distilled 
before use. Water was double glass-distilled and silanised glassware was used throughout. Of 
the derivatisation reagents for gas chromatography-mass spectrometry (GC-MS), 
methoxyamine (MO) hydrochloride and heptafluorobutyric acid anhydride (HFBA) were 
from Sigma-Aldrich, while trimethylsilylimidazole (TMSI) and hexamethyldisilazane 
(HMDS) came from Pierce (Perbio Science Ltd., Cheshire, UK) Lipidex 5000 gel 
(PerkinElmer) was washed before use with cyclohexane and then stored in cyclohexane : 
HMDS : pyridine 98:1:1 (v/v/v). Oasis HLB (5 ml, 200 mg) and MAX (3 ml, 60 mg) solid 
phase extraction cartridges were obtained from Waters Corp., Milford, USA. Ecoscint H 
(National Diagnostics, Yorkshire, UK) was used for scintillation counting. 
 
Brain samples 
Adult male Sprague-Dawley rats (250-450 g) from the breeding colony at Biological Services, 
University College London were kept in a 12 h lighting regimen (lights on at 8.00 h) and fed 
rat chow and water ad libitum. For experiments to test the extraction of endogenous 3H-
progesterone and its metabolites from brain tissue, rats were killed by CO2 inhalation. All 
other rats were killed between 11.00 h and 15.00 h by cervical dislocation. The whole brain 
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(including cerebellum but excluding olfactory bulbs) was rapidly removed and stripped of 
meninges then stored at -70°C until extraction. All animal procedures were given local ethical 
committee approval and performed under licence from the UK Government Home Office. 
 
Tissue extraction and fractionation 
Pooled tissue samples from 2-4 rats were homogenised in 5 volumes of ice-cold potassium 
phosphate buffer (5 mM, pH 7) with a Polytron® blender. A 0.5 ml portion of the homogenate 
was removed to determine blood contamination of the brain samples as described below and 
stored at -20oC. The remaining homogenate was added dropwise to 20 volumes of acetic acid 
(3%, v/v) in 96% ethanol in polypropylene tubes in an ultra-sonicating bath. After further 
sonication for 10 min followed by incubation at -20oC overnight, the extracts were sonicated 
on ice with an MSE Soniprep probe. After a further 30 min on ice, extracts were centrifuged 
at 28000×g for 30 min at 25 oC. Lipid was removed from the supernatants by partitioning 
three times against 10 volumes of isooctane (previously saturated with 77% ethanol in 
potassium phosphate buffer (5 mM, pH 7) plus acetic acid (2.4%, v/v). After drying down 
under vacuum, the extracts were resuspended in 4 volumes 60% ethanol (in H2O, v/v) then 
centrifuged at 1000×g for 12 min, the supernatant (corresponding to up to 8 g of original 
tissue) was passed through a 200 mg reverse phase Oasis hydrophilic-lipophilic balance 
HLB cartridge for the further removal of lipidic material. An additional 4.4 volumes of 60% 
ethanol in potassium phosphate buffer (5 mM, pH 7, v/v) were passed through the cartridge to 
ensure elution of steroids and the combined eluate dried down under vacuum. For separation 
of free and conjugated steroids, the extracts were then redissolved in 3.75 volumes 20% 
ethanol in potassium phosphate buffer and passed through 60 mg reverse phase Oasis mixed-
mode anion exchange MAX cartridges. After a wash with 5 ml 20% ethanol in ammonium 
acetate buffer (20 mM, pH 7, v/v), free steroids were eluted in 4 ml ethyl acetate. Any steroid 
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glucuronides present could then be eluted with 20 ml 60% ethanol in formate/pyridine buffer 
(20 mM, pH 3, v/v). Finally, after a wash with 2 ml ethyl acetate (dried over Na2SO4), the 
steroid sulphates were eluted in 15 ml 50 mM benzene sulphonic acid in ethyl acetate 
saturated with 2 M H2SO4. The free steroid eluates were dried under nitrogen and derivatised 
as described below. Steroid sulphate fractions were solvolysed before derivatisation by 
incubation at 40oC in the acidified ethyl acetate eluant for 16 h in the presence of Na2SO4. 
After neutralisation with pyridine, ethyl acetate was evaporated from these solvolysed 
fractions and the residue extracted three times with 2 ml ether. The combined ether phase was 
dried down for derivatisation by MO-TMSI or HFBA. If the latter, the ether phase was 
washed beforehand three times with 1 ml of H2O. Reagent blank samples were carried 
alongside each tissue sample throughout the above procedures.  
 
Extraction efficiency of ethanol/acetic acid for brain steroids was estimated after ip injection 
of two rats with 0.7 MBq/kg 3H-progesterone in phosphate buffered saline (5 ml/kg). These 
rats were killed after 2.5-3h by CO2 inhalation and their brains quickly removed before 
storage at -70oC. As described above, brains were homogenised in 5 volumes of ice-cold 
potassium phosphate buffer (5 mM, pH 7). The total brain radioactivity was then estimated by 
removing portions of homogenate for solubilisation in 3 volumes Soluene 350. These 
solubilised samples were then bleached with hydrogen peroxide (final concentration of 1% 
w/v) for 2 h at 50oC, before counting in Ecoscint H containing Triton X-100 (6% v/v), glacial 
acetic acid (0.6% v/v) and butylated hydroxytoluene (2% w/v). The remaining homogenate 
was extracted into ethanol/acetic acid as already described. Radioactivity contained in these 
brain extracts was found to be 88.2% of total brain radioactivity.  
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Blood contamination of the brain samples was estimated by the spectrophotometric 
determination of haemoglobin. Portions (0.5 ml) of brain homogenates which had been 
withheld from steroid extraction and stored at -20oC were thawed and centrifuged (28000×g, 
30 min, 4oC). Haemoglobin was then measured in these supernatants by the change in 
absorbance between 560 and 578 nm upon reduction by the addition of sodium dithionite (to a 
final concentration of 10 mM). Changes in absorbance were calibrated with respect to 
haemoglobin standards (Sigma) and the blood content of the original brain samples then 
calculated to be 1.26 ± 0.10% (v/v; mean ± SEM, n=12), assuming a haemoglobin 
concentration in rat blood of 157 g/l (31). 
 
Sample derivatisation 
For samples to be derivatised with MO and TMSI, the internal standards 16-
dehydropregnenolone, 6α-methyl-17-hydroxyprogesterone and prednisolone were added 
beforehand at 50-100 ng. These samples were then dried under nitrogen and redissolved in 
200 µl MO in pyridine (2%, w/v).  In the case of the steroid sulphate fractions, improved 
yields were obtained if samples were reduced in volume to approximately 50 µl after 
dissolving in MO/pyridine (32). Both steroid sulphates and free steroids were incubated with 
MO/pyridine at 60oC for 1 h. The TMSI was then added at 100 µl and the mixture heated a 
further 3 h at 100oC. At the end of this derivitisation, pyridine was evaporated under nitrogen 
and the residue dissolved in cyclohexane : HMDS : pyridine 98:1:1 (v/v/v) and passed 
through a Lipidex 5000 gel column (0.5 cm diameter and 8 cm high). After further elution 
with 2 ml of the same solvent, the pooled eluates were dried under nitrogen and dissolved in 
cyclohexane for injection onto the GC. 
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For samples to be derivatised with HFBA, the internal standard 16-dehydropregnenolone was 
added at 50 ng. After drying under nitrogen, these samples were then redissolved in 30 µl 
benzene and 30 µl HFBA for incubation at 60 oC for 30 min. Following this incubation, 
samples were dried under nitrogen and the residue redissolved in 1 ml cyclohexane : pyridine 
98:2 (v/v) for passage through Lipidex 5000 gel columns. Columns were eluted with a 
further 2 ml of the same solvent and to the pooled eluates the internal standards tetracosane 
and octacosane were then added at 25 ng each. Finally, the samples were dried under nitrogen 
and dissolved in cyclohexane for injection into the GC.  
 
Gas chromatography-mass spectrometry analysis 
All analyses were carried out on a Shimadzu 17A GC coupled to a QP 5050A MS (Shimadzu, 
Milton Keynes, UK), equipped with autosampler AOC-20s. The system was controlled and 
data processed by the Shimadzu Class 5000 software. A 30 m long Zebron ZB1 wall coated 
open tubular column (Phenomenex, Macclesfield, UK) with 0.25 mm inner diameter and 0.25 
µm film thickness was used for GC with helium as the carrier gas at a constant flow rate of 
0.7 ml/min. All analyses were performed in the splitless mode and the injector purge valve 
was opened after 4 min or 2 min for analysis of MO-TMS- or HFB-derivatives, respectively. 
For the analysis of MO-TMS-derivatives, the injector temperature was kept constant at 280oC 
and the pressure at 400 kPa for 5 min. Thereafter the pressure was decreased to 34.2 kPa, 
followed by a rise of 6.5 kPa/min to 81 kPa. After 0.33 min at this pressure, the gradient was 
set at 1.6 kPa/min to a final pressure of 111.7 kPa, which was held for 4 min. The oven 
temperature was at 70oC for 5 min, then rose at 20oC/min to 220oC. After 0.33 min, the 
gradient was 5oC/min to 315oC, which was held for 4 min. The interface temperature was 
constant at 315oC. For analysis of HFB-derivatives, the injector temperature was constant at 
250oC and the pressure at 400 kPa for 2 min. Thereafter, the pressure was decreased to 34.2 
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kPa followed by a rise of 5.9 kPa/min to 79 kPa. After 0.33 min at this pressure, the gradient 
was set at 1.5 kPa/min to 98 kPa, which was held for 5 min. Oven temperature was at 70oC for 
2 min followed by a rise of 20oC/min to 220oC then, after 0.33 min, a rise of 5oC/min to 
285oC, which was held for 5 min. The interface temperature was constant at 285oC. Samples 
were ionised by electron impact ionisation with an energy of 70 eV. The detector voltage was 
at 1.7 kV. For initial characterisation, retention indices after Kovats (33) were determined for 
derivatised reference steroids according to the following equation:  
 
[ ]
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where N is the number of carbon atoms in the alkane eluting before the compound of interest, 
n the increment in number of carbon atoms from this alkane eluting to the one eluting after the 
compound of interest, t(A) the retention time (min) of the compound of interest, t(N) the 
retention time of the alkane eluting before the compound of interest and t(N+n) the retention 
time of the alkane eluting after the compound of interest. For highest possible sensitivity, the 
MS was run in selected ion monitoring (SIM) mode. In two ion SIM of MO-TMS-derivatives, 
pairs of target and qualifier ions for each steroid were monitored in groups of 4 to 6 ions at a 
time such that potentially overlapping pairs did not coincide. The ions were monitored in 4 
different injections with the detector settings changed according to RI as indicated in Table 1.  
 
For confirmation of compound identities, three ions were monitored for MO-TMS-derivatives 
or two ions for HFB-derivatives, in groups of 3 to 6 ions. These ions are shown in Table 2.  
 
Analysis of results 
Peaks were integrated manually and retention time and integration data were further processed 
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in Microsoft Excel. For identification, qualifier to target ion ratios (Q/T) were calculated 
from their areas. Compounds had to meet target values of Q/Ts of reference compounds run 
alongside tissue samples within 0.67 and 1.5 (± 20% of relative abundance of target and 
qualifier ions). Further identification was obtained from relative retention times (RRT). These 
RRTs were calculated as the ratio of retention times of analyte and the closest of one of three 
internal standards. For positive identification in SIM, RRTs of analytes had to lie within 
±0.5% of the RRTs of reference compounds run alongside tissue samples.   
 
For calibration, increasing amounts of reference steroids (0.5-10 ng) were run together with 
fixed amounts (25-100 ng) of internal standards. The ratios of reference to standard target ion 
areas could then be plotted against amount ratios. Regression lines were fitted to these plots, 
which were linear up to 10 ng. Endogenous brain steroids could then be quantified by using 
the area ratio of their target ions to those of the closest internal standard.  
 
Accuracy of this quantitation was examined by assaying mixtures of standards at 0.5, 1.6, 4.0 
and 10.0 ng injected mass per steroid (results shown only for 0.5 ng). The amount of each 
steroid in each sample was determined and the % accuracy calculated as the amount measured 
over the calculated amount. The intra- and inter-assay reproducibilities were calculated from 
the assays carried out for determination of accuracy. The % coefficients of variation (CV) 
were calculated from the standard deviations and means within and between assays (results 
shown only for 0.5 ng).  
 
Detection limits of the overall extraction and assay procedure were determined for brain 
steroids from area ratios of peaks in reagent blanks extracted and assayed alongside the brain 
samples. For detection, area ratios had to be three times those of peaks at the same RRT in the 
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corresponding extraction blank. The concentrations at those three times blank values were 
calculated using the calibration curves. Detection limits shown in Table 3 were the minimal 
values found from all extracts.   
 
Results  
Two ion selected ion monitoring of steroids in rat brain 
The first stage of the present investigation was to screen for a wide range of compounds in 
both the free steroid and sulphate conjugate fractions of rat brain extracts. For this purpose, 
we used gas capillary chromatography-electron impact mass spectrometry (GC-EIMS) in two 
ion selected ion monitoring (SIM) mode after derivatisation of these fractions with MO and 
TMSI. The steroids for which we screened are listed in Table 1. Pure standards of these 
steroids were first used to adjust sample injection, temperature and pressure conditions of the 
gas chromatograph for their optimum resolution as MO-TMS derivatives (see Methods). The 
MO-TMS derivatives of each steroid were then individually analysed for their mass 
spectrometric behaviour. An example of a mass spectrum is shown in Figure 1 for MO-TMS-
pregnenolone. Diagnostic ions for each compound were chosen from their mass spectra 
according to high relative abundance and selectivity, excluding those which might originate 
from overlapping elutions of steroid derivatives. Choice of these diagnostic ions then allowed 
SIM for endogenous brain steroids at increased sensitivity. Usually the ion of higher relative 
abundance was chosen as the target (T) ion for quantitation and the second ion as a qualifier 
(Q) to aid in identification. These ions are also listed for the non-biological steroids which 
were used in the present study as internal standards for quantitation. In order to maintain high 
analytical sensitivity during SIM, the T and Q ions were monitored in groups of no more than 
6 and changed at set times during the elution. To monitor all T and Q ions of the MO-TMS 
derivatives of the compounds listed in Table 1, four separate injections were performed for 
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each sample and altogether four different brain extracts screened in this way. This initial 
screen tentatively identified 32 free steroids and 23 steroid sulphates in the rat brain extracts, 
as indicated in Table 1. Also shown are the accuracy, intra- and inter-assay reproducibilities 
determined at the 0.5 ng level for all compounds in this screening procedure.  
  
Confirmation and quantitation of brain steroids  
Confirmation of the identities of the compounds revealed in the above two ion SIM screening 
was attempted using three ion SIM of their MO-TMS-derivatives and/or two ion SIM of their 
HFB-derivatives. The additional ions for the former derivatives were chosen following the 
same principles as for the two ion SIM methods. Likewise, specific ions were identified for 
two ion SIM of the HFB-derivatives. Figures 2 and 3 illustrate typical chromatograms 
obtained from three ion SIM of MO-TMS-derivatives and from two ion SIM of HFB-
derivatives, respectively. In both Figure 2 and Figure 3, the trace from a brain extract is 
shown below that of the appropriate reference steroid. Examples are shown not only for 
identified brain steroids but also for some of those steroids which were not confirmed as 
present in the brain extracts.    
 
Table 2 lists all 17 free steroids together with one steroid sulphate, DHEA sulphate, which 
met the criteria for unequivocal identification in the present study. This Table 2 also shows 
the diagnostic ions for three ion SIM of MO-TMS-derivatives and for two ion SIM of HFB-
derivatives for each compound and allows comparison of the RRTs and Q/T ratios of brain 
analytes with those of standard steroids. Overall definitive identification of an endogenous 
brain steroid is achieved, if coelution of three ions of the compound derivatised with MO and 
TMSI or of two ions from both the MO-TMS- and HFB- derivatives occurred within the 
RRT- and Q/T-limits of the standard. For such confirmation, the RRTs and Q/T ratios of brain 
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analytes had to be within ±0.5% and 0.67 and 1.5, respectively, of those of standards analysed 
on the same day (see Discussion). Confidence limits at the 99.9% level for RRTs and Q/T 
ratios were also calculated from series of standard samples and found to coincide well with 
the above pragmatic limits (not shown).  
 
Identified rat brain steroids were quantified using two or three ion SIM and their 
concentrations are shown in Table 3. Also shown in this Table are the recoveries for all of the 
steroids screened by two ion SIM in the present study, after their addition as pure standards to 
rat brain homogenates and subsequent extraction, fractionation and derivatisation with MO-
TMSI. In addition, for each steroid, we give the minimal detection limits of the overall 
extraction and fractionation procedure, as determined from reagent blank samples run 
alongside the tissue samples. 
 
Discussion 
The present study has employed ethanolic extraction of steroids from adult male rat brain 
followed by mixed mode hydrophobic interaction and anion exchange chromatography to 
completely separate free steroids and steroid sulphates, prior to their identification and assay 
by gas capillary chromatography-electron impact mass spectrometry (GC-EIMS). Others have 
also used methanol or ethanol to extract free and sulphated steroids from brain tissue (12, 30, 
34, 35). With the addition of acetic acid as a denaturant, Liere et al. (28) obtained comparable 
apparent extraction efficiencies for pregnenolone to those reported here for progesterone. As 
for previous studies, we were unable to estimate extraction efficiencies for steroid sulphates 
because these undergo desulphation after systemic injection and do not remain in the brain in 
significant quantities as the original ester (7, 36). However, the polar steroid sulphates are 
soluble in aqueous ethanol and so should extract more efficiently than the free steroids. 
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Lipoidal steroid conjugates (26) were not analysed in the present study. These would not 
extract well into ethanol and in any case should have been removed during the initial clean-up 
of the extracts by isooctane partitioning and then passage through the HLB cartridges. 
 
After extraction and fractionation, the free steroids and steroid sulphates from rat brain were 
derivatised for identification and assay by GC-EIMS. Identification was based on comparison 
with steroid standards and relied on two criteria: relative retention time (RRT; with respect to 
the nearest internal standard) on the GC and diagnostic ions from the MS. For the former, we 
adopted the European Commission recommendation (37) of only accepting RRTs which fell 
within ± 0.5% of a reference standard analysed under the same conditions. As for diagnostic 
ions in the MS, it was not possible to obtain complete spectra for endogenous brain steroids 
and selected ion monitoring had to be employed in order to increase sensitivity. An initial 
screen of rat brain extracts monitoring only two diagnostic ions for each compound indicated 
the possible presence of 32 free steroids and 23 steroid sulphates. A more rigorous analysis 
then confirmed 17 free steroids plus one steroid sulphate, DHEA sulphate, as present in adult 
male rat brain. To be considered as identified, the brain steroid derivatives had to meet not 
only the ± 0.5% RRT criteria but also to have relative ion abundance for three diagnostic ions 
within ± 20% of the standard. Previous evaluations of mass spectral databases have shown 
such limits on the 3 ion criterion alone to provide an unambiguous identification of target 
compounds (38, 39).  
 
With reference to previous analyses of steroids in nervous tissue (see Introduction), the 
present results confirm the identification of pregnenolone, progesterone, 5α-
dihydroprogesterone, 3α,5α- and 3β,5α-tetrahydroprogesterone, DHEA, DHEA sulphate and 
testosterone in adult male rat brain extracts. The GC-MS analysis reported here has also 
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provided chemical identification for the 3α,5α-tetrahydrodeoxycorticosterone and 
corticosterone previously measured by immunoassay in rat brain. Whole brain concentrations 
of the above steroids were found to be in the same ranges as given in the previous reports 
cited here apart from one study (26), which found approximately 10- to 40-fold higher 
concentrations of pregnenolone, 3α,5α- and 3β,5α-tetrahydroprogesterone and DHEA. In 
addition to the above steroids, we have also identified 20α- and 20β-dihydropregnenolone, 
20α-dihydroprogesterone, 5α,20α-tetrahydroprogesterone, 5α-pregnane-3α,20α-diol, 5α-
pregnane-3α,17-diol-20-one and 5α-pregnane-3α,11β-diol-20-one as present in adult male rat 
brain. None of the steroids identified here has been reported to occur in plasma at 
concentrations which would contribute significantly to the amounts measured in the present 
brain extracts and contamination with blood can be excluded as a source. 
 
In contrast to one previous report which employed two ion SIM on GC-MS (26), 
epiandrosterone was not identified in either the free or the sulphated steroid fractions of male 
rat brain. This steroid was detected in two ion SIM of the sulphate fraction in the present 
study but not confirmed with three ion SIM. The present results also differ from several 
previous reports (see, for example, 2, 26, 28) in failing to detect pregnenolone sulphate in rat 
brain. These previous studies have employed solvent phase partitioning and/or hydrophobic 
interaction chromatography to separate free and sulphated steroids and relied on indirect 
measurements of pregnenolone sulphate in which the ester is solvolysed to yield pregnenolone 
for identification and assay. In retrospect, these earlier measurements of pregnenolone 
sulphate seem likely to have assayed contaminating free steroid or another solvolysable, 
possibly lipoidal, conjugate from the original extract (40). Direct immunoassay of 
pregnenolone sulphate in adult male rat brain reported this conjugate at less than 0.4 ng/g 
adult male rat brain (41) and direct LC-MS failed to detect it at a limit of 0.3 ng/g tissue (35). 
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The present study relied on the solvolysis of sulphate esters but employed prior anion 
exchange chromatography for the complete separation of free steroids from steroid sulphates 
and failed to detect pregnenolone sulphate at a limit of 0.05 ng/g brain (uncorrected for 
procedural losses). This is consistent with recent functional studies in rat hippocampus which 
suggest a role for pregnenolone sulphate as a retrograde synaptic messenger, but only during 
development and not older than postnatal day 5 (42). Nevertheless and in contrast to the lack 
of pregnenolone sulphate in adult male rat brain, we were able to detect DHEA sulphate in 
this tissue. The latter was found at concentrations close to those given in the initial 
characterisation of this rat brain steroid (1).   
 
Steroids identified as present in adult male rat brain by the present study are shown in Figure 
4 in relation to the possible metabolic conversions which could give rise to these compounds. 
The rats used in our study had not been adrenalectomised or gonadectomised and so endocrine 
sources cannot be excluded for some of these brain steroids. Indeed, 3α,5α-
tetrahydrodeoxycorticosterone, corticosterone and testosterone were found in the absence of 
detectable concentrations of their respective precursors, 5α-dihydrodeoxycorticosterone, 11-
deoxycorticosterone and androstenedione, suggesting endocrine origins. Previous studies in 
adrenalectomised and/or castrated rats have suggested endocrine sources for 
tetrahydrodeoxycorticosterone, corticosterone and testosterone in male rat brain (1, 11, 12). 
For corticosterone, the 11-keto metabolite could not be detected, confirming that the 11β-
hydroxysteroid dehydrogenase in brain works predominantly as a reductase and so would not 
attenuate the glucocorticoid receptor actions of this steroid (43). Figure 4 illustrates that 
DHEA was also found in the present survey in the absence of detectable concentrations of its 
known precursor in endocrine tissues. In these tissues, 17α-hydroxypregnenolone is an 
intermediate produced by the enzyme CYP17, which catalyses the conversion of 
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pregnenolone to DHEA and possesses both steroid 17-hydroxylase and 17,20-lyase activities 
(44). The absence of 17α-hydroxypregnenolone in the present extracts is consistent with 
previous investigations which have failed to detect activity of the CYP17 enzyme in adult 
mammalian brain (5, 6). Nevertheless and unlike the above corticosteroids and testosterone, 
DHEA persists in male rat brain after adrenalectomy and castration (1) and is therefore 
thought to arise within this tissue.  
 
For the remaining steroids identified as present in adult male rat brain and shown in black in 
Figure 4, enzymes previously identified in terms of mRNA, protein and/or activity (5, 6) can 
account for their presence. Thus, pregnenolone can be converted to 20α-dihydropregnenolone 
or progesterone by the brain enzymes 20α-hydroxysteroid dehydrogenase or 3β-
hydroxysteroid dehydrogenase/isomerase, respectively. It is unclear at present whether the 
20α-reduced metabolites are formed by a specific 20α-hydroxysteroid oxidoreductase or by 
one of the 3α-hydroxysteroid dehydrogenases (6, 43). The latter can also give rise to 20β-
reduced metabolites which would account for the presence of 20β-dihydropregnenolone, 
although we were unable to detect 20β-dihydroprogesterone. By contrast, the 20α-reduced 
metabolite of progesterone was detected, although only a small proportion of progesterone 
appears to undergo this conversion in rat brain homogenates in vitro (45). 
 
For progesterone, the major metabolic route in rat brain appears to be 5α-reduction to yield 
5α-dihydroprogesterone, on the pathway to the GABAA receptor enhancing metabolite 3α,5α-
tetrahydroprogesterone (see Introduction). Consistent with the 5α-reductase enzyme being the 
highest affinity, rate limiting step on this pathway (46), we could not detect 3α- or 3β-
dihydroprogesterone. The present study also failed to detect 5β-reduced metabolites of 
progesterone, in agreement with the reported lack of 5β-reductase activity in mammalian 
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brain tissue. However, we did find 3β,5α-tetrahydroprogesterone. Unlike their respective 
3α,5α-reduced compounds, the 3β,5α-reduced steroids are not active at the GABAA receptor 
(47). Nevertheless, they would be substrates for the 3β-diol hydroxylase enzyme, which 
hydroxylates at positions 6 or 7, and is found throughout the brain. Competitive inhibition of 
3β-diol hydroxylase increases the duration of anaesthesia induced by 3α,5α-
tetrahydroprogesterone in the rat and this enzyme has therefore been suggested to provide an 
inactivation pathway for 3α,5α-reduced pregnanes and androstanes in the central nervous 
system (48). The 3β,5α-tetrahydroprogesterone found in the present study could have arisen 
through epimerisation of 3α,5α-tetrahydroprogesterone (49) or direct from 5α-
dihydroprogesterone. The latter would serve as a diversion of substrate from the formation of 
neuroactive 3α,5α-tetrahydroprogesterone. 
 
The present results also identify 11β-, 17α- and 20α-hydroxylation as possible routes for the 
inactivation of 3α,5α-tetrahydroprogesterone. The first two metabolites appear to be inactive 
at the GABAA receptor, whereas the latter has partial agonist properties at the 3α,5α-
tetrahydroprogesterone-modulated site (47, 50). An 11β-hydroxylase (CYP11B) is widely 
expressed in brain and usually denoted as the final step in the production of corticosterone 
from deoxycorticosterone. However, the lack of evidence in this and previous studies for 21-
hydroxylase (CYP21) activity and thus deoxycorticosterone formation in brain suggests that 
the 11β-hydroxylase may actually be more important in this tissue for the inactivation of 
3α,5α-tetrahydroprogesterone. Formation of 5α-Pregnane-3α,17-diol-20-one is harder to 
explain in view of the apparent lack of CYP17 activity in brain (see above), although 17-
hydroxylation could result from variable site specificity of one of the 3α-hydroxysteroid 
dehydrogenases (43) or another as yet unknown mechanism. As mentioned above, 20α-
dihydroprogesterone was also detected in the present survey. This steroid is known to be a 
 21 
better substrate than progesterone for rat brain 5α-reductase (51), which would explain the 
presence of 5α, 20α-tetrahydroprogesterone. Further reduction to 5α-pregnane-3α,20α-diol 
may therefore indicate an alternative metabolic route rather than a true inactivation pathway 
for 3α,5α-tetrahydroprogesterone. Likewise, the formation of 20α-dihydropregnenolone may 
serve to divert pregnenolone from the formation of neuroactive progesterone and its 3α,5α-
reduced metabolites. 
 
To conclude, the present study has chemically identified several neuroactive free steroids in 
adult male rat brain. Some of these compounds were found together with precursors 
suggesting they could be formed within this tissue, whereas others appear to enter from 
peripheral sources, although further studies will be necessary to confirm such origins. For 
3α,5α-tetrahydroprogesterone, which is known to enhance the interaction of GABA with the 
GABAA receptor, 11β-, 17α- and 20α-hydroxylated  metabolites were identified, thereby 
implicating inactivation pathways for this potent neuromodulatory compound. Our results also 
confirm the suggestion that epimerisation could serve as a first step on the inactivation of 
3α,5α-reduced steroids in brain. In addition, the presence of 20α- and 20β-reduced 
pregnenolone indicates a possible regulation on the production of progesterone and 3α,5α-
tetrahydroprogesterone. For the steroid sulphates, only DHEA sulphate was confirmed and 
pregnenolone sulphate not detected at limits below those quoted by previous authors. Despite 
its reported effects on GABAA and NMDA receptors, pregnenolone sulphate is therefore of 
doubtful physiological significance in the adult CNS. Further studies are now needed to 
elucidate the regulation of steroid production within the brain and to evaluate how these 
processes interact with peripheral sources of steroid.  
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Table 1. Screen for steroids in rat brain by GC-EIMS using two ion selected ion monitoring of their MO-TMS derivatives  
Systematic name Trivial name RI T Q Injection 
number 
Ion group 
number 
Tentatively 
identified 
Accuracy 
(%) 
Intra-
assay CV 
(%) 
Inter-
assay CV 
(%) 
5-Androsten-3β-ol-17-one Dehydroepiandrosterone 2631 358 268 3 1 FS, SS 124.4±3.8 12.7 6.9 
5α-Androstan-3β-ol-17-one Epiandrosterone 2645 360 270 3 1 SS 109.6±2.5 13.2 5.1 
4-Androsten-3,17-dione Androstenedione 2690* 344 313 4 1  108.5±3.6 10.0 7.3 
4-Androsten-17β-ol-3-one Testosterone 2713* 389 268 4 1 FS, SS 114.7±3.3 8.2 6.4 
5β-Pregnan-3α,17-diol-20-one 17(5β)-OH-Pregnanolone 2740 476 188 2 1 SS 109.3±7.4 8.1 15.1 
4-Pregnen-3α-ol-20-one 3α-Dihydroprogesterone 2746 417 244 1 1 FS,SS 107.7±6.2 16.4 12.9 
5β-Pregnan-3β-ol-20-one 3β,5β-Tetrahydroprogesterone  2752 388 298 1 1 FS, SS 111.9±2.7 12.2 5.5 
5α-Pregnan-3α-ol-20-one 3α,5α-Tetrahydroprogesterone 2757 388 298 1 1 FS, SS 97.6±3.2 6.9 7.3 
5β-Pregnan-3α-ol-20-one 3α,5β-Tetrahydroprogesterone 2764 388 298 1 1 FS, SS 118.5±2.8 12.0 5.2 
5α-Pregnan-3α,17-diol-20-one 17(5α)-OH-Pregnanolone 2766 476 188 2 1 FS, SS 103.0±7.0 7.0 15.1 
5β-Pregnane-3α,20β-diol Pregnanediol 2779 284 269 2 1 FS, SS 103.0±7.0 NM 7.5 
5,16-Pregnadien-3β-ol-20-one 16-Dehydropregnenolone 2802 415 384 1,2,3,4 2 NA NA NA NA 
5α-Pregnane-3α,20α-diol Allopregnanediol 2803 346 269 1 2 FS, SS 125.5±5.0 6.8 9.0 
5β-Pregnane-3α,20α-diol 5β-Pregnane-3α,20α-diol 2811 284 269 2 2 SS 110.2±2.1 11.4 4.3 
4-Pregnen-3β-ol-20-one 3β-Dihydroprogesterone 2818 386 244 3 2 SS 118.8±6.4 9.7 12.1 
5β-Pregnan-3,20-dione 5β-Dihydroprogesterone 2820 343 275 4 2 FS 126.1±5.0 12.1 8.9 
5-Pregnen-3β-ol-20-one Pregnenolone 2834 402 386 1 3 FS, SS 95.0±1.5 14.8 3.6 
5α-Pregnan-3β-ol-20-one 3β,5α-Tetrahydroprogesterone 2847 388 100 1 3 FS, SS 121.7±3.2 9.7 5.9 
5α-Pregnan-3,20-dione 5α-Dihydroprogesterone 2859* 343 275 2 3 FS 110.2±3.3 9.4 6.6 
5-Pregnene-3β,20β-diol 20β-Dihydropregnenolone 2860 372 462 2 3 FS,SS 120.2±3.3 2.5 6.2 
5α-Pregnan-3α-ol-11,20-dione Alfaxalone 2880 402 433 1 4  117.0±1.8 10.1 3.5 
5-Pregnene-3β,20α-diol 20α-Dihydropregnenolone 2882 372 462 1 4 FS 119.4±2.7 12.2 5.0 
4-Pregnen-3,20-dione Progesterone 2900 372 341 4 3 FS 115.6±1.9 18.8 3.7 
5β-Pregnan-3α,21-diol-20-one 3α,5β-Tetrahydrodeoxy-
corticosterone 
2907* 476 188 2 4 FS 118.2±8.0 10.1 15.1 
5α-Pregnan-20α-ol-3-one 5α,20α-
Tetrahydroprogesterone 
2907* 303 289 4 3 FS, SS 107.8±2.5 22.4 5.2 
5α-Pregnan-3α,11β-diol-20-
one 
5α-Pregnan-3α,11β-diol-20-
one 
2921 386 296 1 5 FS, SS 181.1±4.9 14.5 6.1 
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Table 1 continued. 
5-Pregnen-3β,17α-diol-20-one 17α-Hydroxypregnenolone 2921 362 474 1 5 FS 118.6±2.8 14.6 5.2 
5β-Pregnan-3β,21-diol-20-one 3β,5β-Tetrahydrodeoxy-
corticosterone  
2924* 507 358 3 3 FS, SS 110.1±2.6 14.2 5.4 
4-Pregnen-20β-ol-3-one 20β-Dihydroprogesterone 2927 417 286 2 4 FS NM NM NM 
5α-Pregnan-3α,21-diol-20-one 3α,5α-Tetrahydrodeoxy-
corticosterone  
2929* 507 358 3 3 FS, SS 112.7±5.4 11.5 10.8 
4-Pregnen-20α-ol-3-one 20α-Dihydroprogesterone 2947 417 286 3 3 FS, SS 117.5±3.8 13.7 7.3 
4-Pregnen-17α-ol-3,20-dione 17α-Hydroxyprogesterone 2967* 429 339 1 6 FS, SS 112.5±2.7 11.4 5.4 
6α-Methyl-pregnen-17α-ol-
3,20-dione 
6α-Methyl-17-
hydroxyprogesterone 
2970* 443 474 1,2,3,4 6,5,4,4 NA NA NA NA 
5β-Pregnan-21-ol-3,20-dione 5β-Dihydrodeoxy-
corticosterone 
2987 431 462 2 4 FS 122.5±6.7 20.2 12.3 
5α-Pregnan-3β,21-diol-20-one 3β,5α-Tetrahydro-
deoxycorticosterone 
3045 476 188 3 4 FS, SS 115.4±6.0 6.8 11.6 
5α-Pregnan-21-ol-3,20-dione 5α-Dihydrodeoxy-
corticosterone 
3058* 462 431 4 4 FS 103.5±24.3 25.5 47.0 
4-Pregnen-21-ol-3,20-dione 11-Deoxycorticosterone 3098 273 286 2 6 FS, SS 208.5±8.5 10.2 9.1 
4-Pregnen-11β-ol-3,20-dione 11β-Hydroxyprogesterone 3105* 370 339 2 6 FS 130.3±9.0 10.4 15.4 
4-Pregnen-17α,21-diol-3,20-
dione 
Reichstein’s Substance S (or 
11-Deoxycortisol) 
3124* 517 427 3 5 SS 119.6±2.6 17.6 4.8 
4-Pregnen-21-ol-3,11,20-trione 11-Dehydrocorticosterone 3196 443 474 3 5 FS 297.3±14.2 43.3 10.7 
4-Pregnen-17α,21-diol-
3,11,20-trione 
Cortisone 3223* 531 441 4 5  116.2±3.1 6.7 5.9 
4-Pregnen-11β,21-diol-3,20-
dione 
Corticosterone 3247* 548 517 2 7 FS 110.7±2.7 5.6 5.4 
1,4-Pregnadien-11β,17,21-
triol-3,20-dione 
Prednisolone, 1-
Dehydrocortisol 
3280 513 603 1,2,3,4 7,7,6,5 NA NA NA NA 
11β,17α,21-Trihydroxy-4-
pregnen-3,20-dione  
Hydrocortisone, Cortisol 3290 605 515 1 7  247.1±9.4 16.9 14.3 
Retention index (RI, * of first peak in the case of double peaks) plus target (T) and qualifier (Q) ions (m/z) for screening of steroids in adult male rat brain by 
two-ion SIM of their MO-TMS-derivatives in GC-EIMS. Four different rat brain extracts were screened and each injected 4 times into the GC with the MS 
set selectively to monitor different groups of 4-6 diagnostic ions along the elution profile. Steroids are tentatively identified as present in free steroid (FS) 
and/or steroid sulphate (SS) fractions. Also shown are accuracy (%, mean±SEM), intra- and inter-assay coefficients of variation (CV, %) of two ion SIM 
analyses of mixtures of MO-TMS-derivatised steroid standards (for 0.5 ng injected mass). NM: Not measured; NA: not applicable. 
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Table 2. Confirmation of identity for free and sulphate conjugated steroids in adult male rat brain.  
MO-TMS-derivatives HFB-derivatives  
Diagnostic ions Steroid standards Rat brain Diagnostic ions Steroid standards Rat brain 
Steroid T Q1 Q2 RRT Q1/T Q2/T RRT Q1/T Q2/T T Q RRT Q/T RRT Q/T 
Dehydroepiandrosterone  358 268 260 0.911 1.436 1.363 0.909 2.148 0.700 270 255 1.051 0.189 1.050 0.195 
Dehydroepiandrosterone sulphate 358 268 260 0.915 1.442 1.048 0.914 1.934 0.825 270 255 1.050 0.197 1.051 1.327 
Testosterone 389 358 268 0.954* 0.190 0.357 0.953 0.220 0.258 680 451 1.038 0.272 1.038 3.595 
3α,5α-Tetrahydroprogesterone 388 241 298 0.977 0.311 NM 0.976 0.292 NM 496 514 0.959 0.453 0.960 0.439 
5α-Pregnan-3α,17-diol-20-one 476 386 364 0.982 0.231 0.299 0.981 1.955 0.235 442 487 1.032 2.176 1.032 2.207 
5α-Pregnane-3α,20α-diol 117 269 346 0.999 0.022 0.012 1.000 0.057 0.017 712 697 0.969 0.693 0.968 0.550 
Pregnenolone 402 386 312 1.016 1.842 1.071 1.015 1.680 0.901 298 283 1.024 0.201 1.023 0.186 
3β,5α- Tetrahydroprogesterone  243 298 404 1.022 0.482 0.615 1.022 0.624 0.404 467 514 1.036 5.326 1.035 5.101 
5α-Dihydroprogesterone  343 275 288 1.028* 0.497 0.595 1.028 0.602 0.402 NM NM NM NM NM NM 
20β-Dihydropregnenolone  462 372 332 1.028 2.687 0.855 1.027 2.510 1.039 496 481 1.001 0.115 1.000 0.115 
20α-Dihydropregnenolone  462 372 332 0.955 2.360 0.866 0.954 3.167 0.944 496 481 1.032 0.069 1.030 0.074 
Progesterone 372 341 273 0.965 0.924 0.549 0.964 0.973 0.656 510 495 1.023 0.137 1.023 0.187 
5α,20α-Tetrahydroprogesterone  303 288 386 0.968* 0.409 1.666 0.966 0.678 1.464 499 514 0.952 1.583 0.955 1.682 
5α-Pregnan-3α,11β-diol-20-one 386 476 296 0.974 0.379 0.406 0.974 0.623 0.679 469 512 0.977 0.941 0.976 1.156 
3α,5α-Tetrahydrodeoxycorticosterone  476 507 404 0.979 0.318 0.209 0.978 0.278 0.188 499 257 1.060 3.250 1.059 5.876 
20α-Dihydroprogesterone  417 301 296 0.988 0.410 0.330 0.984 0.559 1.802 708 693 1.030 0.204 1.030 0.166 
Corticosterone 548 517 427 0.987 1.070 1.284 0.986 1.317 1.407 738 491 1.110 1.253 ND ND 
 
 
Qualifier (Q) and target (T) diagnostic ions, relative retention times (RRT, * of first peak in the case of double peaks), Q/T ratios of standard compounds and 
brain extracts from three ion SIM of their MO-TMS-derivatives or two ion SIM of their HFB-derivatives. Values outside identification limits are shown in 
italic. ND: not detected; NM: not monitored.  
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Table 3. Quantitation of steroids in adult male rat brain 
 Free steroids Steroid sulphates 
Steroid Concentration 
 (ng/g) 
Detection limit 
(ng/g) 
Recovery % Concentration 
(ng/g) 
Detection limit 
(ng/g)  
Recovery % 
Dehydroepiandrosterone  0.27±0.20 0.004 59.9±0.7 1.04±0.83 0.14 51.3±2.3 
Testosterone  
 2.24±0.95 0.007 53.0±1.2 ND 0.17 NM 
Pregnenolone  1.67±0.45 0.05 39.8±1.0 ND 0.05 28.6±2.2 
20α-Dihydropregnenolone  0.27±0.08 0.05 38.1±1.1 ND 0.04 NM 
20β-Dihydropregnenolone  0.17±0.06 0.03 36.8±0.7 ND 0.17 NM 
Progesterone  0.70±0.14 0.09 63.1±3.4 NA NA NA 
5α-Dihydroprogesterone   1.01±0.30 0.12 31.5±3.9 NA NA NA 
3α,5α-Tetrahydroprogesterone      0.35±0.09 0.06 39.3±1.1 ND 0.21 NM 
3β,5α-Tetrahydroprogesterone  0.13±0.05 0.05 36.4±0.8 ND 0.16 NM 
20α-Dihydroprogesterone  0.19±0.08 0.002 46.5±0.7 ND 0.19 NM 
5α,20α-Tetrahydroprogesterone  0.25±0.11 0.01 40.9±2.6 ND 0.09 NM 
5α-Pregnane-3α,20α-diol  0.25±0.09 0.07 55.9±3.2 ND 0.11 NM 
5α-Pregnan-3α,17-diol-20-one  0.06±0.02 0.02 49.9±1.8 ND 0.18 NM 
5α-Pregnan-3α,11β-diol-20-one  0.77±0.70 0.005 43.3±2.5 ND 0.08 NM 
3α,5α-Tetrahydrodeoxycorticosterone  0.20±0.05 0.006 41.4±2.1 ND 0.02 NM 
Corticosterone 4.63±1 1.02 43.7±5.8 ND 0.32 NM 
3β,5α-Tetrahydrodeoxycorticosterone ND 0.03 37.0±2.4 ND 0.03 NM 
Epiandrosterone  ND 0.006 57.8±0.5 ND 0.02 NM 
Androstenedione  ND 0.03 71.2±1.3 NA NA NA 
3α-Dihydroprogesterone  ND 0.09 21.0±2.3 ND 0.16 NM 
3β-Dihydroprogesterone  ND 0.06 27.3±3.1 ND 0.06 NM 
5β-Dihydroprogesterone ND 0.27 35.2±2.0 NA NA NA 
11β-Hydroxyprogesterone  ND 0.33 63.8±4.7 ND 0.55 NM 
17α-Hydroxypregnenolone  ND 0.07 47.6±1.4 ND 0.06 NM 
17α-Hydroxyprogesterone  ND 0.12 58.5±1.4 ND 0.15 NM 
20β-Dihydroprogesterone  ND 0.01 NM ND 0.01 NM 
3β,5β-Tetrahydroprogesterone  ND 0.07 42.2±1.1 ND 0.21 NM 
3α,5β-Tetrahydroprogesterone  ND 0.04 39.4±1.1 ND 0.02 NM 
Alphaxalone  ND 0.009 48.5±1.9 ND 0.02 NM 
5β-Pregnan-3α,17-diol-20-one  ND 0.04 52.0±4.9 ND 0.03 NM 
5β-Pregnane-3α,20β-diol  ND 0.14 36.3±3.8 ND 0.06 NM 
5β-Pregnane-3α,20α-diol  ND 1.02 29.5±0.8 ND 1.11 NM 
11-Deoxycorticosterone  ND 0.35 109.9±33 ND 0.81 NM 
5α-Dihydrodeoxycorticosterone  ND 0.44 45.0±1.1 ND 0.25 NM 
5β-Dihydrodeoxycorticosterone  ND 0.03 35.9±0.8 ND 0.01 NM 
3α,5β-Tetrahydrodeoxycorticosterone  ND 0.005 35.4±2.7 ND 0.005 NM 
3β,5β-Tetrahydrodeoxycorticosterone  ND 0.03 44.3±4.0 ND 0.004 NM 
Cortisol ND 0.04 12.8±2.3 ND 0.04 NM 
11-Deoxycortisol ND 0.06 49.0±4.4 ND 0.05 NM 
11-Dehydrocorticosterone ND 3.06 34.0±9.3 ND 1.50 NM 
Cortisone ND 0.10 21.9±3.4 ND 0.05 NM 
 
Concentrations of MO-TMS- or HFB-derivatives of steroids in pooled male rat brain extracts analysed by 2 and 3 
ion SIM are given in ng/g tissue (means ± SEM, n≥3). Detection limits (ng/g tissue) were determined from reagent 
blanks carried alongside tissue samples through the whole extraction and fractionation procedure. Recoveries (%, 
mean±S.E.M., n=4) are also shown for pure standards added to brain homogenates and carried through entire 
procedure. ND: not detectable; NA: not applicable; NM: not measured.   
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Figure 1. EI-mass spectrum (99-800 m/z) of pregnenolone derivatised with MO and 
TMSI and proposed fragmentation pathways.  
Ion abundance is shown in arbitrary units. 
 
 
Figure 2. Typical chromatograms of male rat whole brain extracts analysed in GC-
EIMS by selected ion monitoring of MO-TMS-steroid derivatives.  
Traces from brain extracts are shown below those of reference compounds. Examples are 
given of both positively identified and non-detectable brain steroids.  Ion (m/z as shown) 
abundance is plotted against relative retention time (RRT) to one of three internal standards as 
indicated in parentheses: 16-dehydropregnenolone (1), 6α-methyl-17-hydroxyprogesterone 
(2), prednisolone (3). The * indicates expected RRT. For clarity of presentation, most traces 
are shown base-shifted (no y-axis drawn).  
 
 
Figure 3. Typical chromatograms of male rat whole brain extracts analysed in GC-
EIMS by selected ion monitoring of HFB-steroid derivatives.  
Traces from brain extracts are shown below those of reference compounds. Examples are 
given of both positively identified and non-detectable brain steroids.  Ion (m/z as shown) 
abundance is plotted against RRT to one of three internal standards as indicated in 
parentheses: tetracosane (1), 16-dehydropregnenolone (2), octacosane (3). The * indicates 
expected RRT. For clarity of presentation, most traces are shown base-shifted (no y-axis 
drawn).  
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Figure 4. Identified pathways of steroid synthesis and metabolism in adult male rat 
brain.  
Compounds identified in the present study are shown in black and those not detected left in 
red. For clarity, the 5β-pregnanes not detected in the present study have been omitted from the 
scheme. Enzymes previously identified at activity, protein or mRNA levels by others (see 
Discussion) are also shown in black and again, those not found shown in red. Abbreviations 
are as follows: CYP11A1, cholesterol side chain cleavage; CYP17, 17α-hydroxylase/c17,20-
lyase; 3β-HSD, 3β-hydroxysteroid dehydrogenase/isomerase; CYP21, 21-hydroxylase; 11β-
HSD, 11β-hydroxysteroid dehydrogenase; 17β-HSD, 17β-hydroxysteroid dehydrogenase; 
3α/β-HSD, 3α/β-hydroxysteroid dehydrogenase; 17α-HOlase, 17α-hydroxylase; 20α-HSD, 
20α-hydroxysteroid dehydrogenase; CYP11B, 11β-hydroxylase.  
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